Alzheimer’s disease (AD) is the most common neurodegenerative disorder, currently affecting more than 55 million people worldwide — a number projected to reach 139 million by 2050. Although therapeutic strategies targeting β-amyloid (Aβ), tau pathology, and neuroinflammation have been extensively investigated, current treatments provide primarily symptomatic relief and are unable to halt or reverse the underlying pathology. Identifying novel therapeutic targets therefore remains an urgent clinical priority.
Microglia are the principal innate immune effector cells of the central nervous system. In AD, danger signals such as Aβ aggregates, tau fibrils, and damage-associated molecular patterns activate the NLRP3 inflammasome in microglia. Activated caspase-1 then cleaves gasdermin D (GSDMD) to form membrane pores, inducing pyroptotic microglial death, while processing pro-IL-1β and pro-IL-18 into their mature forms — amplifying neuroinflammation and driving neuronal degeneration. Growing evidence indicates that mitochondrial dysfunction is a major upstream driver of NLRP3 activation: damaged mitochondria release excessive reactive oxygen species (ROS) and mitochondrial DNA that directly promote inflammasome assembly. Yet pharmacological agents that specifically target mitophagy in AD remain scarce.
Icariin (ICA), a major flavonoid extracted from the traditional medicinal herb Epimedium, is well documented for its anti-inflammatory, antioxidant, and neuroprotective properties. However, whether ICA can enhance mitophagy in the context of AD — thereby reducing mitochondria-derived inflammatory signals and suppressing NLRP3/GSDMD-mediated pyroptosis — had remained unknown.
In a study published in
Chinese Journal of Natural Medicines, researchers from the Second Xiangya Hospital of Central South University systematically addressed this question using APP/PS1 transgenic mice and Aβ1-42-stimulated BV-2 microglia, combining behavioral testing, histological analysis, transcriptomic profiling, immunofluorescence, molecular docking, molecular dynamics simulation, cellular thermal shift assay, Mdivi-1 co-treatment, and siRNA-mediated Pink1 knockdown.
The study first confirmed that ICA significantly improved cognitive deficits in APP/PS1 mice across multiple behavioral paradigms — nest-building, novel object recognition, Y-maze, and Morris water maze tests — and reduced microglial overactivation (IBA1⁺/CD68⁺) and pro-inflammatory cytokine levels (IL-6, TNF-α) in the hippocampus. Transcriptomic and experimental analyses showed that ICA upregulated mitophagy-related genes including
Pink1,
Lc3b,
Atg4b, and
Becn1, alleviated mitochondrial swelling and cristae disruption observed by transmission electron microscopy, restored mitochondrial membrane potential, and reduced excessive ROS accumulation
in vitro, accompanied by enhanced LC3/TOM20 colocalization.
At the target level, molecular docking and a 100-ns molecular dynamics simulation suggested that ICA stably engages PINK1 (involving residues Arg-544, Lys-552, and Trp-378, with a predicted binding free energy of −11.46 kcal·mol⁻¹), and a cellular thermal shift assay demonstrated increased thermal stability of PINK1 upon ICA exposure — supporting PINK1 as an upstream target of ICA-induced mitophagy. Mechanistic validation showed that
Pink1 knockdown weakened ICA-induced LC3/TOM20 colocalization and partially reversed ICA’s inhibition of NLRP3, GSDMD, and IL-1β/IL-18 release in Aβ1-42-stimulated microglia; in APP/PS1 mice, co-treatment with the mitophagy inhibitor Mdivi-1 similarly attenuated ICA’s anti-inflammatory and anti-pyroptotic effects. Notably, analysis of the human hippocampal transcriptomic dataset GSE36980 revealed elevated NLRP3, IL18R1, and GSDMD expression in AD patients, supporting the pathological relevance of this pathway in human disease. Importantly, long-term ICA administration (100 consecutive days) produced no detectable organ toxicity or hematologic abnormalities, indicating a favorable safety profile.
This study establishes an “ICA–PINK1 mitophagy–NLRP3/GSDMD pyroptosis” regulatory axis: by improving mitochondrial quality control, ICA limits mitochondrial stress and subsequently dampens inflammasome-associated inflammatory injury. Compared with highly selective NLRP3 inhibitors that have encountered safety limitations in clinical development, ICA simultaneously improves mitophagy, restores mitochondrial homeostasis, and suppresses inflammasome activation — positioning this natural flavonoid as a promising multi-target pharmacological candidate for reducing microglia-driven neuroinflammation and slowing AD progression.
The work entitled “
Icariin enhances PINK1-associated mitophagy to attenuate NLRP3/GSDMD-related microglial pyroptosis and cognitive impairment in Alzheimer’s disease” was published in
Chinese Journal of Natural Medicines (published in October, 2026).
DOI: 10.1016/S1875-5364(26)61213-7